The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma

被引：68

作者：

Bower, Mark ^{[1
]}

Weir, Justin ^{[2
]}

Francis, Nicholas ^{[2
]}

Newsom-Davis, Tom ^{[1
]}

Powles, Sam ^{[1
]}

Crook, Tim ^{[1
]}

Boffito, Marta ^{[3
]}

Gazzard, Brian ^{[3
]}

Nelson, Mark ^{[3
]}

机构：

[1] Chelsea & Westminster Hosp, Dept Oncol, London SW10 9NH, England

[2] Chelsea & Westminster Hosp, Dept Histopathol, London SW10 9NH, England

[3] Chelsea & Westminster Hosp, Dept HIV Med, London SW10 9NH, England

来源：

AIDS | 2009年 / 23卷 / 13期

关键词：

HAART; HIV; Kaposi's sarcoma; ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE-DEFICIENCY-SYNDROME; SWISS HIV COHORT; LOW VIRAL LOAD; PROTEASE INHIBITORS; CANCER-RISK; SUPPRESSION; TRIALS; INDIVIDUALS;

D O I：

10.1097/QAD.0b013e32832d080d

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Objective: A prospective cohort study was performed to evaluate the clinical Outcomes of patients with histologically confirmed AIDS-related Kaposi's sarcoma diagnosed since the introduction of HAART. Methods: Two hundred and fifty-four consecutive patients (96% men) diagnosed with Kaposi's sarcoma between 1996 and 2008 are included. Clinicopathological and treatment details were prospectively collected. The median follow-up is over 4 years and maximum 12 years. Results: The mean age at Kaposi's sarcoma diagnosis was 39 years and average duration of known HIV seropositivity was 4 years. At Kaposi's sarcoma diagnosis, only 19% patients were on HAART and only 7% patients had all undetectable plasma HIV viral load. Seventy-nine (31%) patients had AIDS clinical Trial Group stage T1 disease at Kaposi's sarcoma diagnosis and 122 (48%) had AIDS clinical Trial Group stage 11 disease (CD4 cell count < 150 cells/mu l). Nodular grade Kaposi's sarcoma represented 28% of the tumours and was significantly associated with black African ethnicity and AIDS clinical Trial Group T1 stage disease. The overall 5-year Survival is 89% (95% confidence interval 84-93). One hundred and sixty-three patients were treated with HAART alone for TO stage Kaposi's sarcoma; only one died of Kaposi's sarcoma and only 37 (22%) required chemotherapy, giving a systemic treatment-free survival at 5 years of 74% (95% confidence interval 67-82) and the overall Survival at 5 years is 91% (95% confidence interval 87-95). Conclusion: The high success rate of HAART in a large cohort of AIDS-Kaposi's sarcoma patients over a prolonged period of follow-up will reassure patients and clinicians that this is a well tolerated and effective approach to stage TO Kaposi's sarcoma. (C) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins

引用

页码：1701 / 1706

页数：6

共 43 条

[41] A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy [J].

Stebbing, J ;

Sanitt, A ;

Nelson, M ;

Powles, T ;

Gazzard, B ;

Bower, M .

LANCET, 2006, 367 (9521) :1495-1502

[42] AIDS-associated Kaposi's sarcoma associated with a low viral load and a high CD4 cell count [J].

Stebbing, Justin ;

Powles, Tom ;

Bower, Mark .

AIDS, 2008, 22 (04) :551-552

[43] Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma [J].

Tam, HK ;

Zhang, ZF ;

Jacobson, LP ;

Margolick, JB ;

Chmiel, JS ;

Rinaldo, C ;

Detels, R .

INTERNATIONAL JOURNAL OF CANCER, 2002, 98 (06) :916-922

← 1 2 3 4 5 →